

NEUROGENESIS, INC.

DELAWARE COMPANY

QUARTERLY REPORT

As of December 31, 2013

Item 1: The exact name of the issuer and its predecessors.

The exact name of the Issuer is **Neurogenesis, Inc.**

Item 2: The address of its principal executive offices:

Neurogenesis, Inc.
120 Park Avenue
League City, TX, 77573
Phone: 281.557.7877, 800.862.5033
Email: albieser@neurogenesis.com
Website(s): neurogenesis.com, neurogenesis.tv, itsabouthealth.net

Item 3: Security Information.

A. Par or Stated Value for each class of Securities

Security Symbol: NEUN
CUSIP Number 64124F 301
Common Stock Authorized: 1,000,000,000 authorized, Par Value \$0.00001
Common Stock Outstanding: 82,262,136 as of 12-31-2013

B. Number of shares or total amount of securities outstanding for each class of securities outstanding

Period end date: December 31, 2013

Authorized Shares: 1,000,000,000

Outstanding Shares: 82,262,136

Public Float: 8,608,600

Number of Beneficial Shareholders: 1

Total number of Shareholders: 99

(The Company's outstanding shares of this filing date of March 31, 2014 is 82,433,156)

Period end date: June 30, 2013
Authorized Shares: 1,000,000,000
Outstanding Shares: 76,404,061
Public Float: 46,552,461
Number of Beneficial Shareholders: 1
Total number of Shareholders: 99

Period end date: December 31, 2012
Authorized Shares: 1,000,000,000
Outstanding Shares: 67,104,092
Public Float: 41,039,992
Number of Beneficial Shareholders: 1
Total number of Shareholders: 97

Period end date: December 31, 2011
Authorized Shares: 1,000,000,000
Outstanding Shares: 65,000,092
Public Float: 41,039,992
Number of Beneficial Shareholders: 1
Total number of Shareholder: 97

C. Transfer Agent

Gulf Registrar and Transfer Corporation
P. O. Box 8207
Bacliff, TX, 77518
Phone: 281-339-2451

This Transfer Agent Registered under the Exchange Act and regulated by the SEC.

Item 4: Issuance History

15,158,044 shares issued during the twelve month period ended December 31, 2013

9,299,969 shares issued during the six month period ended June 30, 2013.

Item 5: Financial Statements

(The following Annual financial statements are incorporated by reference.

- Balance Sheet for December 31, 2013
- Statement of Income for the twelve month period ended December 31, 2013
- Statement of changes in stockholders' equity as of December 31, 2013

- Statement of cash flows for the twelve Month Period ended December 31, 2013

Off-Balance Sheet Arrangements

There are no off balance sheet arrangements.

Legal Proceedings

None

Item 6 Issuer's Business, Products and Services

A. A description of the issuer's business operations;

Neurogenesis is in the business of formulating and causing to be manufactured and marketing nutritional supplements of a particular type. All of this Company's products are designed to increase the health of people suffering from a variety of mental and physical health issues, such as addictions and other physical issues such as hyperactivity, effects of anxiety and reactions to stressful situations.

B. Date and State of Incorporation;

Incorporated on April 19, 1989 in the state of Delaware.

C. The issuer's primary SIC code:

Primary	2383
Secondary	2834

D. The issuer's fiscal year end date;

December 31

E. Principal products or services, and their markets;

Nutritional supplements marketed to United States, New Zealand, Canada, Australia, the Far East and Europe

Item 7 Issuer's Facilities

Offices, warehousing, shipping and wholesale operations leased at 120 Park Avenue, League City, TX 77573.

The terms of the lease are:

Monthly Rent of \$3000.00, plus prorated monthly electricity expense, based on building square footage. (The lease expired and has been

extended on a month-by-month basis for over a year. The building is for sale and landlord has all tenants on this arrangement.)

Item 8 Officers, Directors and Control Persons

A. Officers, Directors and Control Persons. In responding to this item, please provide the following information for each of the issuer's executive officers, directors, general partners and control persons, as of the date of this information statement.

Albert H. Bieser: President/CEO, Treasurer, Chairman of the Board;

Paul Brown: Corporate Secretary;

Karen Coady: _ Director _____

Jeffrey Lewis: _ Director _____

Frank W. Bieser: ___ Director _____

Brian Thompson: _ Director _____

B. Legal - Disciplinary History.

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other misdemeanor offenses);

None.

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None.

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the SEC, the CFTC, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None.

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited such person's involvement in any type of business or securities activities.

None.

C. Beneficial Shareholders

<u>Name of Beneficial Owner</u>	Shares of Common Stock <u>Owned</u>	<u>%</u>
Albert H. Bieser 15535 St. Cloud Drive Houston, TX 77062	29,851,600	39.00

Item 9 Third Party Providers

The name, address, telephone number, and email address of each of the following outside providers that advise the issuer on matters relating to the operations, business development and disclosure:

1. Investment Banker:

None.

2. Promoters:

None.

3. Counsel:

Stacy L. Barnes, Managing Partner
Firm:
5248 Larkin Street, Suite A
Houston, TX 77007
Phone: 832-460-9191

4. Accountant or Auditor:

Accountant or Auditor
Name: Gary Schulz, Richard Russell
Firm: Russell, Craft & Schulz
17225 El Camino Real, Suite 250
Houston, TX 77058
Phone: 281-286-3400, Ext 12
Email: garyscpa@sbcglobal.net

5. Public Relations Consultant:

None

6. Investor Relations Consultant:

None

7. Advisory:

None

Item 10 Issuer's Certificate

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

The certifications shall follow the format below:

I, Albert H. Bieser, President and Treasurer of Neurogenesis, Inc., certify that:

1. I have reviewed this Quarterly Statement of Neurogenesis, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

March 31, 2014

s/s Albert H. Bieser,

Albert H. Bieser, President/Treasurer

